Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Recruiting

Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable CancersTesting the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05803382

Conditions

Metastatic Colorectal Carcinoma

Metastatic Malignant Solid Neoplasm

Stage IV Colorectal Cancer AJCC v8

Unresectable Colorectal Carcinoma

Unresectable Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BET Bromodomain Inhibitor ZEN-3694

Biopsy

Biospecimen Collection

Capecitabine

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-03-25.